Preparation of labeled aromatic amino acids <i>via</i> late-stage <sup>18</sup>F-fluorination of chiral nickel and copper complexes
作者:Austin Craig、Niklas Kolks、Elizaveta A. Urusova、Johannes Zischler、Melanie Brugger、Heike Endepols、Bernd Neumaier、Boris D. Zlatopolskiy
DOI:10.1039/d0cc02223c
日期:——
A general protocol for the preparation of 18F-labeled AAAs and α-methyl-AAAs applying alcohol-enhanced Cu-mediated radiofluorination of Bpin-substituted chiral complexes using Ni/Cu-BPX templates as double protecting groups is reported. The chiral auxiliaries are easily accessible from commercially available starting materials in a few synthetic steps. The versatility of the method was demonstrated
[EN] NOVEL PEPTIDE BASED PCSK9 VACCINE<br/>[FR] VACCIN PCSK9 À BASE DE NOUVEAUX PEPTIDES
申请人:CADILA HEALTHCARE LTD
公开号:WO2018189705A1
公开(公告)日:2018-10-18
The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases.
Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
[EN] IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE<br/>[FR] PRODUITS PHARMACEUTIQUES PEPTIDIQUES AMÉLIORÉS CONTRE L'INSULINORÉSISTANCE
申请人:MEDERIS DIABETES LLC
公开号:WO2015184177A1
公开(公告)日:2015-12-03
Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
[EN] GLP RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR GLP
申请人:HEPTARES THERAPEUTICS LTD
公开号:WO2021186166A1
公开(公告)日:2021-09-23
The disclosures herein relate to novel compounds of formula (1 ): and salts thereof, wherein Q, W, X, Y, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, LysR, R1, R2 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide (GLP) receptors.